Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS ONE. 2009; 4(4): e5033.
Published online 2009 April 3. doi:  10.1371/journal.pone.0005033
PMCID: PMC2660411

The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas

Kathrin Maedler, Editor


microRNAs (miRNAs) are known to play an essential role in controlling a broad range of biological processes including animal development. Accordingly, many miRNAs are expressed preferentially in one or a small number of cell types. Yet the mechanisms responsible for this selectivity are not well understood. The aim of this study was to elucidate the molecular basis of cell-specific expression of the pri-miR-375 gene, which is selectively expressed in pancreatic islets, and has been implicated both in the development of islets, and the function of mature pancreatic beta cells. An evolutionarily conserved 768 bp region of DNA upstream of the pri-miR-375 gene was linked to GFP and luciferase reporter genes, and expression monitored in transgenic mice and transfected cultured cells. Deletion and targeted mutagenesis analysis was used to evaluate the functional significance of sequence blocks within the upstream fragment. 5′-RACE analysis was used for mapping the pri-miR-375 gene transcription start site. The conserved 768 bp region was able to direct preferential expression of a GFP reporter gene to pancreatic islets in transgenic mice. Deletion analysis using a luciferase reporter gene in transfected cultured cell lines confirmed the cell specificity of the putative promoter region, and identified several key cis-elements essential for optimal activity, including E-boxes and a TATA sequence. Consistent with this, 5′-RACE analysis identified a transcription start site within this DNA region, 24 bp downstream of the TATA sequence. These studies define the promoter of the pri-miR-375 gene, and show that islet-specific expression of the pri-miR-375 gene is controlled at the transcriptional level. Detailed analysis of the transcriptional mechanisms controlling expression of miRNA genes will be essential to permit a comprehensive understanding of the complex role of miRNAs such as miR-375 in developmental processes.


microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression through post-transcriptional mechanisms [1]. Accumulating evidence indicates that miRNAs play a central role in controlling a broad range of biological activities including embryonic development, cell proliferation, metabolic homeostasis and apoptosis [2]. Mammalian genomes contain over 400 miRNA genes [3]. A significant percentage of these are nested within introns or exons of protein coding genes: in these cases, expression of the corresponding miRNAs appears to be under the transcriptional control of the host gene [4]. On the other hand, many miRNA genes are located in intergenic regions, and constitute autonomous expression units that are transcribed by RNA polymerase II [5] into capped and polyadenylated precursors (pri-miRNAs). Sequential processing by the nuclear RNase Drosha and the cytoplasmic RNase Dicer generates the ~22 nt mature miRNA. Upon incorporation to the RISC complex, miRNAs can inhibit expression of genes by promoting degradation of mRNA, or inhibition of translation [6].

Detailed analyses of expression patterns of miRNAs has demonstrated that a significant number of miRNAs are expressed in highly selective spatial and temporal patterns [7], [8]. The molecular basis for this selectivity is not well understood, in large part because relatively little is known about the structure and function of miRNA gene promoters. As a result, it has been difficult to discriminate between transcriptional [9] and post-transcriptional regulation [10]. miR-375 is selectively expressed in pancreatic islets [8], [11]. It appears to play an important role in mature islet cell function, in part by inhibiting expression of myotrophin, a protein implicated in exocytosis [11], [12]. A role for miR-375 has also been demonstrated in pancreatic islet development, through use of morpholino oligonucleotides to reduce expression of miR-375 in developing zebrafish embryos [13]. These results are consistent with recent experiments in mice demonstrating that global inhibition of microRNA biogenesis by deletion of Dicer in embryonic pancreas leads to defects in pancreatic islet development [14].

The mechanisms controlling selective expression of protein coding genes of the endocrine pancreas have been extensively studied [15], [16]. It is well established that regulation is exerted primarily at the transcriptional level through multiple cis-elements located in the promoter regions: these activities typically involve lineage-restricted transcription factors such as Pdx-1, NeuroD1 (BETA2) and MafA [17][19] which interact in synergistic fashion to generate specificity [20]. The aim of the current study was to determine the molecular basis for the selective expression of the pri-miR-375 gene in pancreatic islets. Through generation of reporter plasmids, we were able to functionally characterize the pri-miR-375 promoter. The promoter shows selective activity in islets of transgenic mice and in transfected beta cells, demonstrating that regulation of cell-specific expression is mediated at the transcriptional level.

Materials and Methods

Ethics statement

All animal work was conducted according to relevant national and international guidelines. The experiments were approved and overseen by the Institutional Animal Care and Use Committee (IACUC) of the Weizmann Institute of Science.


Sequence conservation was examined using the UCSC genome browser ( Sequence alignment of genomic DNA sequences was performed using NCBI-BLAST ( and software from GCG. Identification of transcription factor binding sites was performed using Genomatix suite programs MatInspector ( and TESS (

Plasmid constructions

Plasmids for promoter activity measurements were constructed using pGL3-basic vector (Promega) or the TK-luc vector [21]. The region upstream to the miR-375 gene (putative miR-375 promoter region) was generated by PCR using primers 5′ - GAAGATCTTGAGGTACATCGCAGAGGCCAG - 3′ (top) and 5′ - CATGCCATGGGGGCCGGAGCGGAAGACCC - 3′ (bottom) with template of genomic DNA. The PCR fragment was sub-cloned into pGEMTeasy vector (Promega), and ligated to pGL3-basic (SmaI site), creating construct 375a, or to TK-luc. Constructs 375d and 375g were generated by inserting blocks 1+2 and block 1 respectively, using PCR reaction with appropriate primers (Table S1), and construct 375a as template. Constructs 375b and 375f were generated by digesting construct 375a with BglII and HindIII. Construct 375c was generated by digesting plasmid 375a with StuI and HindIII. Construct 375e was generated by digesting plasmid 375a with StuI and BglII. For specific mutagenesis of the promoter, the insert from construct 375b was sub-cloned to pBS (Stratagene) creating plasmid pBS-375b. Plasmids bearing specific mutations were generated from construct pBS-375b using Quick™Change Site-Directed mutagenesis approach (Stratagene). All mutated inserts were fused to the firefly luciferase reporter gene in vector pGL3 using the unique sites NheI and XhoI.

Cell culture

The following established cell lines were used in this study: HIT M2.2.2 (Hamster beta cells) [22], [23], βTC1 [24], and CHO (Chinese hamster ovary cells). Cells were grown in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 I.U./ml) and streptomycin (100 µg/ml).

Transient transfections

Transfection experiments with HIT and CHO cells were carried out using the calcium phosphate co-precipitation technique [25]. Transfections were performed in either 10 cm or 6 well tissue culture plates (Falcon). The 10 cm plates contained 2×106 cells (HIT cells) or 7×105 cells (CHO) and the 6 well plates contained 4×105 cells (HIT) or 2×105 cells (CHO). When transfections were performed in 10 cm plates, the DNA mixture consisted of 2 µg reporter construct and 250 ng internal control plasmid. The total amount of DNA was equalized to 10 µg by adding pUC18. When transfections were performed in 6 well plates, the DNA mixture consisted of 0.5 µg reporter construct and 62.5 ng internal control plasmid. When expression plasmids were used, 1 µg of each was added. The total amount of DNA per transfection was equalized to 3 µg by adding pUC18. The precipitates were left on the cells for 4–7 h, and cells were then exposed to 20% glycerol (HIT) or 10% glycerol (CHO) in DMEM for 2 min. The glycerol was then diluted with PBS (Ca2+/Mg2+ free), removed, and fresh medium was added. Cells were harvested 48 h after transfection, and extracts were subjected to assays to determine the activity of reporter enzymes. Under these conditions, efficiency of transfection was typically 20–40% as determined by use of GFP reporter plasmids.

Luciferase assays

Firefly luciferase and renilla luciferase assays were carried out as follows: whole cell extracts containing 5–50 µg (1–5 µl) of protein were added to 100 µl of either firefly luciferase assay buffer (20 mM Tricine, 0.1 mM EDTA, 1.07 mM (MgCO3)4Mg(OH)2*5H2O, 2.67 mM MgSO4, 3.3 mM DTT, 270 mM Coenzyme A, 470 mM Luciferin (Promega #E1602) and 530 mM ATP, pH 7.8.) or renilla luciferase assay buffer (0.1 M K2HPO4 and 0.1 M KH2PO4, pH 7.4, and 0.5 mM Coelenterazine (Calbiochem)). The samples were placed in a luminometer (LUMAC Biocounter M2500 or Modulus microplate, Turner Biosystems) and light output was determined over a 10 second interval. Firefly luciferase activity was normalized according to the activity of renilla luciferase.

Transgenic mice containing a miR-375-EGFP construct

A plasmid (miR-375-EGFP) containing the mouse miR-375 gene upstream region (768 bp) was generated by replacement of the firefly luciferase open reading frame in pGL3-375a with the EGFP open reading frame (ORF) from the plasmid pEGFP-N1 (using XbaI and BglII sites). A DNA fragment (MluI-SalI) containing the miR-375 promoter and the EGFP ORF (devoid of vector sequences) was purified and microinjected to fertilized mouse oocytes. Microinjection was performed in the Weizmann Institute veterinary facility following standard protocols. Microinjected mouse embryos were transferred into the oviduct of foster females. Genotyping of tail tips was performed using the EGFP primers; top 5′ -AAGTTCATCTGCACCACCG- 3′ and bottom 5′- TCCTTGAAGAAGATGGTGCG -3′. This procedure yielded 4 independent transgenic mice expressing GFP.

Immunofluorescence analysis of pancreas from miR-375-EGFP transgenic mice

Transgenic miR-375-EGFP mice were dissected and examined under an Olympus binocular microscope (SZX12) for GFP detection. The pancreas was then removed, washed in PBS and fixed in 4% PFA for 4 h at 4°C. Tissue was then incubated over-night in 70% ethanol and embedded in paraffin. Slides were de-paraffinized and subjected to antigen retrieval (10 mM sodium citrate, 0.5 mM citric acid, pH 6.0). Endogenous peroxidase activity was inhibited by incubation with hydrogen peroxide (3% H2O2 in 20% methanol). Slides were washed again with PBS and PBST (0.2% Triton X-100), blocked with CASblock (Zymmed laboratories), and then incubated overnight at 4°C with the following primary antibodies diluted in CASblock: rabbit anti-GFP 1[ratio]100 (Molecular Probes, A6455), guinea pig anti-insulin 1[ratio]200 (DAKO, A0564), mouse anti-somatostatin 1[ratio]200 (Beta Cell Biology Consortium) and mouse anti-glucagon 1[ratio]300 (Beta Cell Biology Consortium). Slides were then washed and secondary antibodies diluted in CASblock were applied for 1 h at room-temperature (Cy5 anti-rabbit, Cy3 anti-mouse and Cy2 anti-guinea pig). Slides were then washed again and stained with DAPI for nuclear staining. Finally, slides were mounted with aqueous mounting medium (IMMCO). For immunohistochemistry, slides were incubated with DAB substrate kit for peroxidase (Zymmed laboratories). Selective expression of GFP in pancreatic tissue was observed in all 4 transgenic mice examined. Quantitative co-expression data was obtained from a representative animal. Expression of GFP in insulin-positive cells was evaluated in 12 different fields ( 165 cells); expression of GFP in glucagon-positive cells was evaluated in 8 different fields (165 cells); expression of GFP in somatostatin-positive cells was evaluated in 7 different fields (90 cells).

5′ Rapid amplification of cDNA ends (5′-RACE)

First strand cDNA was synthesized from 5 µg of DNase-treated RNA prepared from HIT cells transfected with pGL3-375a construct, using reverse transcriptase (Affinity Script; Stratagene) according to the manufacturer's instructions. The primer used (bot. 375 NcoI, Table S1) was complementary to a sequence in the middle of block 4, located upstream to the firefly luciferase gene. The cDNA was purified using an PCR purification kit (RBC), and eluted in 40 µl DDW. A poly-G tail was added to the cDNA 3′ end using terminal deoxynucleotidyl transferase (TDT) (Promega) by incubating the purified cDNA with 1× TDT buffer (Promega), 0.83 mM dGTP and 20 U of enzyme at 37°C for 1 h. The reaction was stopped by heating to 65°C for 15 min. Following a second purification, cDNA was eluted in 50 µl of DDW. PCR was performed using the Expand high fidelity PCR system (Roche), with 5 µl of cDNA and 30 pmol of a reverse primer located nested to the primer used for reverse transcription, and a forward primer: GAATTC(C)24. PCR conditions were: 94°C 2 min; 30 cycles (of 94°C 30 sec, 60°C 30 sec, 72°C 3 min); followed by an additional incubation at 72°C for 5 min. The primer used for the PCR reaction was a bottom primer complementary to block 3 (Bot. block 3 BglII, Table S1). An aliquot of the PCR product was resolved on a 1% agarose gel. The resulting band was excised from the gel, purified, sub-cloned into pGEMT-Easy vector (Promega) and then sequenced. The transcription start site was identified as the sequence immediately adjacent to the poly C sequence.

Statistical analysis

Analysis was performed using two way ANOVA. After establishing overall significance of the F-test, pairs of means were compared by the Tukey test (p = 0.05). InStat software (version 2.01) was used to evaluate standard error of the mean (SEM).


Identification of conserved regions upstream of miR-375

Important control elements can often be discovered by a careful inspection of the genomic sequence conservation among different species [26]. Therefore, we compared the region upstream of the pre-miR-375 sequence (miRBase accession # MI0000792) among several vertebrate orthologs. We identified four highly conserved sequences, which we named blocks 1–4 (Fig. 1). Block 1 is 156 bp long, is 59% identical between mouse and human, and is located 585 bp upstream from the pre-miR. Block 2 is 190 bp long, and is 66% identical between mouse and human. Block 3 is 71 bp long, and is 75% identical between mouse and human, and block 4 is 149 bp long, with 75% identity between mouse and human.

Figure 1
miR-375 gene regulatory region.

Function of pri-miR-375 promoter in vivo

In order to test the ability of these sequences to control gene expression in vivo, we fused a 768 bp DNA fragment containing the four conserved blocks (Fig. 1) to the GFP gene. The construct was microinjected into mouse oocytes and expression of GFP was monitored in developing embryos and adult transgenic mice. Strong GFP expression was seen in the pancreas of adult mice (Fig. 2A) and immunofluorescence microscopy revealed GFP expression within the islets (Fig. 2B). GFP was expressed in beta cells (97% of beta cells co-express GFP), in alpha cells (89% co-expression) and in delta cells (91% co-expression) (Fig. 2B). Immunohistochemical analysis confirmed that GFP is expressed at high levels in pancreatic islet cells, and at much lower levels in pancreatic exocrine cells (Fig. 2C). A small number of GFP positive cells were found scattered fairly evenly throughout the exocrine pancreas (Fig. 2B,C). We examined the expression of GFP in 4 mice, each derived from an independent microinjected oocyte. The selectivity of expression for pancreatic tissue was observed in all 4 mice (data not shown). Since this pattern of expression in different animals presumably results from independent insertions into random genomic loci, we conclude that the region upstream of miR-375 contains the pri-miR-375 gene promoter, and is capable of directing GFP expression selectively to pancreatic islets in vivo.

Figure 2
Expression of GFP in pancreas and islets of miR-375-EGFP transgenic mice.

Characterization of the pri-miR-375 transcription start site

In order to confirm that the 768 bp upstream of miR-375 contains a functional promoter, we wished to identify the transcription start site of the endogenous pri-miR-375 transcript. Using the 5′-RACE procedure with mRNA derived from the beta cell line βTC1 [24], we were unable to identify a discrete band corresponding to the start site of the endogenous pri-miR-375, presumably because of rapid processing of the precursor molecule [27]. As an alternative approach, we performed 5′-RACE using RNA derived from the beta cell line βTC1 transfected with a plasmid containing the 768 bp upstream region linked to the luciferase reporter gene. For the PCR reaction, we used a primer corresponding to a sequence located in the middle of block 4. A discrete band was obtained from this reaction (Fig. 3A, lane 1), whereas this band was not seen in control reactions (Fig. 3A, lanes 2–3). The resulting band was analyzed by DNA sequencing. The sequence indicated a transcription start site 259 bases upstream of the pre-miR-375 start (marked with large arrowhead in Fig. 3B, and an arrow in Fig. 3C). Strikingly, this putative start site is 24 bases downstream of an evolutionarily conserved TATA box located at the 3′ end of conserved block 2. Additional 5′-RACE experiments performed using primers distributed in the miR-375 regulatory region identified the same start site (not shown). Although in some sporadic cases, additional bands were obtained (marked with small arrowheads in Fig. 3B), sequence analysis showed that they were either non-relevant (sequences unrelated to miR-375) or shorter species, most likely resulting from premature polymerase termination caused by high GC content, or stable secondary structure of the pri-miR-375. These data suggest that transcription of the pri-miR-375 indeed initiates 24 bases downstream of the conserved TATA box, and that the conserved blocks 1 and 2 contain the promoter of the miR-375 gene.

Figure 3
Mapping of transcription start site of miR-375 gene by 5′-RACE.

Characterization of the pri-miR-375 promoter

To functionally characterize the miR-375 promoter, the fragment consisting of blocks 1 and 2 was fused to a firefly luciferase reporter gene and transfected into pancreatic beta and non-beta cell lines (Fig. 4, fragment 375b). For comparison, we used the promoter of the herpes simplex virus thymidine kinase (TK) gene, which shows low constitutive activity in many cells types [23]. The fragment 375b directed 32-fold higher luciferase gene expression than the TK promoter in beta (HIT) cells (Fig. 4). On the other hand, activity of the fragment was weaker than the TK promoter in CHO cells. Preferential activity of the pri-miR-375 promoter was also seen on comparison with an additional non-beta cell line NIH-3T3 (data not shown). Thus the fragment indeed possesses promoter activity that is manifested preferentially in beta cells. Indeed, the promoter activity of construct 375b was remarkably high, since it showed approximately 45% of the activity of the insulin promoter (Fig. 4), which is considered to be a very strong beta cell promoter [15]. Consistent with the activity observed in mouse pancreatic alpha cells (Fig 2B), construct 375b also showed high activity (approximately 20-fold higher than the TK promoter) in the alpha cell line αTC1 (data not shown).

Figure 4
Activity of the miR-375 promoter in cultured cells.

To determine the contribution of the conserved sequence blocks to the activity of the 375b fragment, deletion analysis was performed (Fig. 5A). Removal of block 1 (construct 375c) led to 3-fold reduction in activity, while beta cell specificity was maintained in this construct (data not shown). Deletion of the ~100 bp at the 3′ end of block 2, containing the conserved TATA box, led to a dramatic (75-fold) reduction in activity (construct 375d). Unexpectedly, the presence of conserved blocks 3 and 4 in the context of blocks 1+2 or block 2, reduced activity substantially, suggesting that blocks 3 and 4 may contain a negatively-acting element. Taken together, these data show that blocks 1 and 2 contain the promoter of the pri-miR-375 gene, and that the TATA box area is critical for promoter activity.

Figure 5
Mapping of transcriptional regulation regions by deletion analysis.

Since mammalian transcriptional control regions often contain transcriptional enhancers, we tested the ability of the upstream miR-375 sequences to activate transcription from the heterologous promoter TK. Indeed fragment 375a (corresponding to blocks 1–4) was able to activate the TK promoter 6-fold in HIT cells (Fig. 5B) but showed essentially no effect on the TK promoter in non-beta cells (CHO) (data not shown). Substantial activation was still maintained upon inversion of the fragment relative to the promoter (Fig. 5B). Similar results were obtained with block 1 (Fig. 5B). We conclude that sequences in the conserved region within block 1 possess features characteristic of a transcriptional enhancer.

Mutational analysis of block 1 and block 2

It has previously been shown that E-boxes (consensus sequence CAxxTG) play an important role in directing selective expression of beta cell specific promoters [20]. Indeed three conserved E-box elements are present in the promoter sequence (Fig. 6A,B). We mutated each of these E-boxes and measured luciferase activity following transfection to HIT cells. Mutation of E-boxes 1, 2 and 3 led to reductions of 47%, 71% and 47% of activity, respectively, as compared to the wild type construct (Fig. 6C). Likewise, mutation of the TATA box caused a 56% reduction in activity (Fig. 6C). Bioinformatics analysis using the MatInspector program (Genomatix) revealed potential binding sites for several beta-cell transcription factors: HNF1, HNF6, AP1, INSM1, XFD3 and PTF1, within the most conserved region of block 2 (Fig. 6B). Mutation 1 (perturbing the consensus binding site for AP1, XFD3, and HNF6) led to a small loss of activity (reduction of 20%), whereas mutation 2 (perturbing the consensus binding site for INSM1, and HNF1) led to a much larger loss in activity (reduction of 84%). This experiment therefore identifies multiple cis-elements required for full activity of the miR-375 promoter.

Figure 6
Mutagenesis of putative transcription factor-binding sites.

To further examine the idea that the conserved E-boxes of the miR-375 promoter act as binding sites for transcription factors of the bHLH family, we tested the effects of the dominant negative HLH proteins Id2 and Id3 [28]. As a control, we first verified that both Id2 and Id3 expression vectors were able to inhibit insulin promoter activity, showing that the constructs were functional under the experimental conditions (Fig. 6D). Both Id2 and Id3 significantly repressed the activity of the miR-375 promoter (38% and 33% respectively, Fig 6D) as compared to transfections performed in the absence of Id-encoding plasmids. Consistent with this, the effect of the Id proteins on the promoter fragment mutated in one of the E-boxes (E-box 2), was less pronounced. These results suggest that the E-boxes within the promoter are functioning at least in part by interaction with transcription factors of the bHLH family.


miRNAs are emerging as critical regulators of a broad range of developmental processes [1]. In order to understand how miRNAs function, major efforts have focused on the identification of bona fide target genes. For example, miRNAs have recently been shown to regulate expression of the pancreatic developmental factors Ngn3 and Foxa2 [29][31]. On the other hand, the appreciation that many miRNAs show highly selective patterns of expression underscores the importance of elucidating the mechanisms that regulate miRNA biogenesis, which is currently poorly understood. For protein coding genes, the central role of transcription initiation in regulating expression levels is well established. However, in recent years, it has become clear that a wide variety of post-transcriptional mechanisms can also significantly affect expression. The aim of this study was to determine whether transcriptional control plays a significant role in directing cell-specific expression of the pri-miR-375 gene which is expressed selectively in pancreatic islets. Using functional assays, we have been able to show that an evolutionarily conserved region upstream of the gene can confer selective expression of a reporter gene, both in transgenic mice and in transfected tissue culture cells. Deletion analysis identified a number of conserved cis-elements required for optimal activity, including a TATA sequence. Consistent with this, we have identified the major transcription start site 24 bp downstream of the TATA sequence. These data represent the first characterization of a pancreas-specific miRNA gene promoter, and demonstrate that cell-specific expression is regulated at least in part, at the level of transcription. This does not exclude possible involvement of post-transcriptional control mechanisms, and indeed a recent study raises the possibility that expression of miR-375 in the developing endocrine pancreas may be controlled in part by selective processing [32].

Our study provides some indications of transcription factors that may be involved in regulating the activity of the pri-miR-375 promoter. One region within block 2 that was particularly sensitive to mutation contains consensus binding sequences for the factors HNF1 and INSM1, which have been previously implicated in development and function of pancreatic islets [33]. Our mutational analysis also showed that E boxes are required for full transcriptional activity. This raises the possibility that the miR-375 gene may be regulated by bHLH transcription factors such as Ngn3 and NeuroD1, which are known to play a central role in pancreas endocrine development and in mature beta cell function respectively [33]. Indeed, recent chromatin immunoprecipitation experiments have shown that NeuroD1 interacts with conserved sequences both upstream and downstream of the miR-375 gene [34]. In the same study, the key pancreatic transcription factor Pdx-1 was also shown to interact with the upstream region, raising the possibility that these factors cooperate in activating transcription, as has been found with other beta cell-specific promoters e.g. the insulin gene promoter. Interestingly, this region contains no Pdx-1 consensus target sites, suggesting that the action of Pdx-1 may be indirect. Taken together, these results suggest that selective expression of miR-375 is controlled by a number of transcription factors that participate in the transcriptional cascade that shapes pancreatic development, and is therefore consistent with the possibility that miR-375 itself is a component of this cascade

Thus far, relatively few potential targets of miR-375 have been experimentally validated [11]. Recently, PDK1, a mediator of the PI3K/PKB signaling cascade, was identified as a potential target of miR-375; in the same study, glucose was shown to inhibit production of miR-375 [35]. Since activation of the PI3K cascade can lead to increased beta cell proliferation, these finding may represent a mechanistic link between glucose and beta cell proliferation. This may be of considerable physiological importance, since glucose has been proposed as a potential mediator of beta cell hyperplasia in insulin resistant states such as obesity and pregnancy [36]. The possibility that glucose modulates miR-375 expression through regulation of promoter activity needs to be further explored.

The large number of miRNA genes combined with the potential of each miRNA to regulate multiple target mRNAs, implies a regulatory network of great complexity. This is consistent with the pleiotropic effects observed in numerous studies, such as those involving global inhibition of miRNA production by ablation of the Dicer gene [14], [37]. On the other hand, experiments involving loss of function of miRNAs often show surprisingly mild phenotypes [38], [39]. To resolve this apparent paradox, it has been proposed that miRNAs may act to confer robustness on genetic programs [40]. Thus, miRNAs may repress “leaky” expression of genes that are not required in a particular biological setting [41]. Alternatively, miRNAs may be required to buffer stochastic variations in expression of genes An important feature of these models is the hypothesis that key transcription factors may regulate target genes both directly and indirectly, through modulation of expression of miRNAs [42].

It is becoming apparent that miRNAs are integral components of transcriptional regulatory networks underlying the development and maintenance of differentiated cell types. The identification of miR-375 as a likely target for key pancreatic transcription factors further strengthens the emerging notion that miRNAs are involved in regulatory networks controlling pancreatic development. More detailed analyses of the transcriptional control mechanisms controlling miR-375 and other selectively expressed miRNA genes will help to shed light on these networks, and permit a more detailed understanding of many aspects of cell function in both physiological and pathological states.

Supporting Information

Table S1

Supplementary data

(0.05 MB DOC)


We thank Dr. Yuval Dor and Tomer Nir for valuable advice, provision of reagents and instruction in immunostaining procedures. We thank the members of the Hornstein and Walker labs for many constructive suggestions. MDW is the Incumbent of the Marvin Meyer and Jenny Cyker Chair of Diabetes Research at the Weizmann Institute. EH is the Incumbent of the Helen and Milton A. Kimmelman Career Development Chair.


Competing Interests: The authors have declared that no competing interests exist.

Funding: Supported by research grants from the Juvenile Diabetes Research Foundation, New York (to MDW and EH), from D-CURE Diabetes Care in Israel (to MDW) and from Mrs. Judith Bennatar (to MDW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. [PubMed]
2. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9:219–230. [PubMed]
3. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–144. [PMC free article] [PubMed]
4. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A. 2007;104:17719–17724. [PubMed]
5. Lee Y, Kim M, Han J, Yeom KH, Lee S, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J. 2004;23:4051–4060. [PubMed]
6. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205. [PubMed]
7. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12:735–739. [PubMed]
8. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401–1414. [PMC free article] [PubMed]
9. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–743. [PubMed]
10. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008;320:97–100. [PubMed]
11. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–230. [PubMed]
12. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500. [PubMed]
13. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol. 2007;5:e203. [PMC free article] [PubMed]
14. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD, et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 2007;56:2938–2945. [PubMed]
15. Walker MD, Edlund T, Boulet AM, Rutter WJ. Cell-specific expression controlled by the 5′ flanking region of insulin and chymotrypsin genes. Nature. 1983;306:557–561. [PubMed]
16. Wilson ME, Scheel D, German MS. Gene expression cascades in pancreatic development. Mech Dev. 2003;120:65–80. [PubMed]
17. Huang HP, Chu K, Nemoz-Gaillard E, Elberg D, Tsai MJ. Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. Mol Endocrinol. 2002;16:541–551. [PubMed]
18. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 1998;12:1763–1768. [PubMed]
19. Zhao L, Guo M, Matsuoka TA, Hagman DK, Parazzoli SD, et al. The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J Biol Chem. 2005;280:11887–11894. [PubMed]
20. Glick E, Leshkowitz D, Walker MD. Transcription factor BETA2 acts cooperatively with E2A and PDX1 to activate the insulin gene promoter. J Biol Chem. 2000;275:2199–2204. [PubMed]
21. Boshart M, Kluppel M, Schmidt A, Schutz G, Luckow B. Reporter constructs with low background activity utilizing the cat gene. Gene. 1992;110:129–130. [PubMed]
22. Santerre RF, Cook RA, Crisel RMD, Sharp JD, Schmidt RJ, et al. Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic beta cells. Proc Natl Acad Sci USA. 1981;78:4339–4343. [PubMed]
23. Edlund T, Walker MD, Barr PJ, Rutter WJ. Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5′ flanking elements. Science. 1985;230:912–916. [PubMed]
24. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, et al. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci (USA) 1988;85:9037–9041. [PubMed]
25. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, et al. DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci (USA) 1979;76:1373–1376. [PubMed]
26. Pennacchio LA, Rubin EM. Genomic strategies to identify mammalian regulatory sequences. Nat Rev Genet. 2001;2:100–109. [PubMed]
27. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell. 2004;16:861–865. [PubMed]
28. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990;61:49–59. [PubMed]
29. Joglekar MV, Parekh VS, Mehta S, Bhonde RR, Hardikar AA. MicroRNA profiling of developing and regenerating pancreas reveal post-transcriptional regulation of neurogenin3. Dev Biol. 2007;311:603–612. [PubMed]
30. Joglekar MV, Parekh VS, Hardikar AA. New pancreas from old: microregulators of pancreas regeneration. Trends Endocrinol Metab. 2007;18:393–400. [PubMed]
31. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem. 2007;282:19575–19588. [PubMed]
32. Joglekar MV, Joglekar VM, Hardikar AA. Expression of islet-specific microRNAs during human pancreatic development. Gene Expr Patterns. 2009;9:109–113. [PubMed]
33. Chakrabarti SK, Mirmira RG. Transcription factors direct the development and function of pancreatic beta cells. Trends Endocrinol Metab. 2003;14:78–84. [PubMed]
34. Keller DM, McWeeney S, Arsenlis A, Drouin J, Wright CV, et al. Characterization of pancreatic transcription factor Pdx-1 binding sites using promoter microarray and serial analysis of chromatin occupancy. J Biol Chem. 2007;282:32084–32092. [PubMed]
35. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, et al. miR-375 targets PDK1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes. 2008;57:2708–2717. [PMC free article] [PubMed]
36. Gleason CE, Gross DN, Birnbaum MJ. When the usual insulin is just not enough. Proc Natl Acad Sci U S A. 2007;104:8681–8682. [PubMed]
37. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, et al. Dicer is essential for mouse development. Nat Genet. 2003;35:215–217. [PubMed]
38. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science. 2005;308:833–838. [PubMed]
39. Harris KS, Zhang Z, McManus MT, Harfe BD, Sun X. Dicer function is essential for lung epithelium morphogenesis. Proc Natl Acad Sci U S A. 2006;103:2208–2213. [PubMed]
40. Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006;38(Suppl):S20–24. [PubMed]
41. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, et al. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature. 2005;438:671–674. [PubMed]
42. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell. 2007;26:753–767. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science